Top Markets
Coin of the day
Brii Biosciences Limited Brii Biosciences Limited

Brii Biosciences Limited

2137
주식 순위 #22138
Founded in Beijing, China, in 2017, Brii Biosciences Limited is a... Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.
주가
$0.12984512
마지막 동기화: 2026-08-21
시가총액
$93.64M
변동 (1일)
3.57%
변동 (1년)
-49.27%
국가
CN
거래 Brii Biosciences Limited (2137)

카테고리

Brii Biosciences Limited (2137)의 주가 이력
최고 종가: $0.12 (2026-08-01 기준)

최저 종가: $2.91 (2021-07-01 기준)
Brii Biosciences Limited의 주가 이력 (2021 ~ 2026)
연간 주가 성과
연도 성과
2026 (TTM) -4.52%
2025 66.95%
2024 -60.43%
2023 -71.76%
2022 -77.93%
2021 0.00%
유사 기업 또는 경쟁사의 주가
회사 주가 변동률 1년% 국가
$547.71 38.62%
US
$1.04K 58.06%
NL
$145.75 437.43%
US
$118.70 -15.60%
AU
$770.19 8.98%
CH